On October 9, Sandieji Pharmaceutical Technology Co., Ltd. announced that the company and its wholly-owned subsidiary Sandieji Pharmaceutical Technology Co., Ltd. have signed a cooperation and license agreement with Johnson & Johnson. The two sides will jointly develop a novel oral drug. Johnson & Johnson Venture Capital, a venture capital agency under Johnson & Johnson, simultaneously made equity investments in Tritiary.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.